Cost Analysis of Ropinirole versus Levodopa in the Treatment of Parkinson's Disease
- Publication date
- Publisher
Abstract
Background: Not all patients with Parkinson's disease (PD) respond to levodopa and others develop dyskinesias. Ropinirole, a dopamine agonist, is associated with fewer dyskinesias than levodopa. Objective: To examine the economic impact of reducing dyskinesias using ropinirole instead of levodopa plus benserazide in PD was examined. The research question addressed was: is the added cost of ropinirole offset by savings due to avoided cases of dyskinesia? Methods: A cost-minimisation analysis was performed from both the societal and Ministry of Health (MoH) of Ontario, Canada perspectives, using 5-year data from a study of dyskinesia outcomes comparing ropinirole with levodopa plus benserazide. A predictive model was developed to capture resource utilisation over 5 years, such as medication costs, medical consultations, hospital admissions, nursing home admissions, caregiver time and productivity loss. The model was based on a previously reported clinical trial which determined dyskinesia rates to be 20% for ropinirole and 45% for levodopa. Standard costing lists were used, and costs were discounted at various rates. Constant 1999 Canadian dollars (Can)wereapplied,andnoincreaseswereassumedoverthetimehorizonoftheanalysis.Amultivariatesensitivityanalysiswithchangesinkeyparameterswasalsoperformed.Results:Fromasocietalperspective,ropinirolewascostsaving.FromtheMoHperspective,theanalysisyieldedanincrementalexpecteddailycost/patientofCan4.41 for substituting levodopa plus benserazide with ropinirole. Ropinirole resulted in daily savings/patient of $Can0.17 in non-drug healthcare costs. In the sensitivity analysis, the direction of results did not change despite changes of 15 to 20% in key parameters, suggesting robustness of the model. Conclusions: From the societal perspective, in comparison with levodopa plus benserazide, the added cost of ropinirole is offset by savings due to avoided cases of dyskinesia.Antiparkinsonians, Cost minimisation, Levodopa/benserazide, Parkinson's disease, Pharmacoeconomics, Ropinirole